上海医药
(601607)
| 流通市值：495.08亿 | | | 总市值：658.23亿 |
| 流通股本：27.89亿 | | | 总股本：37.08亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 70,762,515,910.94 | 275,250,934,889.66 | 209,628,733,748.35 | 139,413,145,524.43 |
| 营业收入 | 70,762,515,910.94 | 275,250,934,889.66 | 209,628,733,748.35 | 139,413,145,524.43 |
| 二、营业总成本 | 68,666,635,360.52 | 267,676,306,689.98 | 203,433,368,171.18 | 134,890,168,760.01 |
| 营业成本 | 63,506,163,809.96 | 244,619,261,051.98 | 186,451,657,820.93 | 123,245,160,906.41 |
| 税金及附加 | 203,040,337.53 | 777,882,162.93 | 594,968,107.05 | 399,683,856.73 |
| 销售费用 | 2,761,184,548.83 | 12,713,976,431.27 | 9,479,577,316.82 | 6,565,066,731.16 |
| 管理费用 | 1,324,505,376.52 | 5,689,841,057.16 | 4,141,832,679.17 | 2,869,292,396.18 |
| 研发费用 | 497,023,575.09 | 2,394,433,810.21 | 1,616,147,379.76 | 1,105,025,665.85 |
| 财务费用 | 374,717,712.59 | 1,480,912,176.43 | 1,149,184,867.45 | 705,939,203.68 |
| 其中:利息费用 | 444,079,216.64 | 1,856,737,428.35 | 1,386,795,389.33 | 917,770,462.06 |
| 其中:利息收入 | 83,493,464.18 | -522,385,724.64 | 363,295,309.41 | -256,781,245.84 |
| 加:公允价值变动收益 | 37,803,333.92 | 203,853,796.87 | 142,203,088.18 | 114,288,629.44 |
| 加:投资收益 | 171,737,957.97 | 380,426,728.73 | 343,492,522.94 | 246,362,833.06 |
| 资产处置收益 | -903,048.37 | 187,967,998.85 | 145,825,666.77 | 139,310,426.73 |
| 资产减值损失(新) | 33,522,644.21 | -614,373,564.47 | -64,752,427.06 | -36,526,101.71 |
| 信用减值损失(新) | -255,373,359.39 | -226,162,119.97 | -432,215,046.79 | -293,255,759.06 |
| 其他收益 | 63,722,035.39 | 634,371,906.48 | 338,847,559.91 | 137,740,088.49 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 2,146,390,114.15 | 8,140,712,946.17 | 6,668,766,941.12 | 4,830,896,881.37 |
| 加:营业外收入 | 18,741,253.82 | 156,399,886.6 | 34,087,049.36 | 15,062,616.9 |
| 减:营业外支出 | 12,414,360.44 | 277,106,289.03 | 58,476,727.59 | 23,938,822.28 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 2,152,717,007.53 | 8,020,006,543.74 | 6,644,377,262.89 | 4,822,020,675.99 |
| 减:所得税费用 | 512,523,535.93 | 2,149,995,228.86 | 1,621,079,199.01 | 1,224,657,639.37 |
| 六、净利润 | 1,640,193,471.6 | 5,870,011,314.88 | 5,023,298,063.88 | 3,597,363,036.62 |
| 持续经营净利润 | 1,640,193,471.6 | 5,870,011,314.88 | 5,023,298,063.88 | 3,597,363,036.62 |
| 归属于母公司股东的净利润 | 1,333,070,453.48 | 4,552,528,438.69 | 4,054,178,132.43 | 2,941,911,373.69 |
| 少数股东损益 | 307,123,018.12 | 1,317,482,876.19 | 969,119,931.45 | 655,451,662.93 |
| (一)基本每股收益 | 0.36 | 1.23 | 1.09 | 0.79 |
| (二)稀释每股收益 | 0.36 | 1.23 | 1.09 | 0.79 |
| 八、其他综合收益 | -3,441,851.94 | -62,617,948.59 | -26,585,406.09 | -35,643,937.69 |
| 归属于母公司股东的其他综合收益 | -6,179,668.62 | -38,190,495.76 | -34,848,867.09 | -32,412,529.77 |
| 九、综合收益总额 | 1,636,751,619.66 | 5,807,393,366.29 | 4,996,712,657.79 | 3,561,719,098.93 |
| 归属于母公司股东的综合收益总额 | 1,326,890,784.86 | 4,514,337,942.93 | 4,019,329,265.34 | 2,909,498,843.92 |
| 归属于少数股东的综合收益总额 | 309,860,834.8 | 1,293,055,423.36 | 977,383,392.45 | 652,220,255.01 |
| 公告日期 | 2025-04-29 | 2025-03-28 | 2024-10-30 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |